- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06868966
Implications of Myelin in Executive Control in Adolescence and Early Adulthood (MYELEX)
August 25, 2025 updated by: Centre Hospitalier St Anne
The Myelex study is a fundamental research study that aims to better understand how the brain functions and develops.
The objective of this study is to better understand the role of myelin, a sheath that surrounds nerve fibers and determines the speed of information propagation in the brain, in cognitive functioning during development in adolescents and young adults.
investigator use Magnetic Resonance Imaging (MRI) because this method allows us to study the anatomy and functioning of the brain in a non-invasive (no injection) and painless manner.
investigator focus on cognitive control, a set of cognitive functions in the prefrontal cortex, at the front of the brain, that enable the use of the best strategies on a case-by-case basis to solve problems effectively.
These functions are closely associated with academic and professional success and develop late, continuing until early adulthood.
The goal of this project is simple: to measure the myelin of nerve fibers using MRI and to evaluate the link with the development of cognitive control.
Each participant will undergo an MRI examination and cognitive assessments.
The study takes place at the Clinical Research Center of GHU Paris and lasts a total of 3.5 hours, including reception, setup, MRI recording, and the completion of a series of cognitive tasks.
Study Overview
Status
Recruiting
Conditions
Detailed Description
Selection visit
- Call for participants for pre-selection
- Sending of information forms by mail
- Making an appointment for the inclusion visit Inclusion visit at GHU Paris.
- Information on the modalities, constraints and foreseeable risks of the study
- Collection of informed consent
- Verification of inclusion/non-inclusion criteria
Clinical examination: o Verification of medical history and drug treatments
- Psychiatric pathology in first-degree relatives
- Consumption of toxic substances (nicotine, alcohol, cannabis, etc.)
- Manual lateralization will be assessed by the score on the Edinburgh questionnaire (Oldfield, 1971)
- Blood sample to measure pubertal hormones (testosterone, estradiol and progesterone levels)
- Collection of main medical history and concomitant treatments
- Explanation of study procedures
- MRI examination
- Cognitive assessment
Study Type
Observational
Enrollment (Estimated)
128
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Arnaud Cachia
- Phone Number: +33 06 61 51 92 00
- Email: arnaud.cachia@u-paris.fr
Study Locations
-
-
-
Paris, France, 75013
- Recruiting
- GHU Ste Anne
-
Contact:
- Arnaud Cachia
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Yes
Sampling Method
Non-Probability Sample
Study Population
Healthy adolescent and adult volunteers aged 10 to 25 years with no contraindications for an MRI examination.
Description
Inclusion Criteria:
- Male or female; Subject aged 10 to 25 years; Right-handed preference; Subject, or legal representative, who has given consent to participate; Native language: French; Subject affiliated with a social security system; Having signed their consent to participate (and their legal representative if applicable), subjects and parents have read the information letter and given their free and informed consent. In cases where only one parent gives consent (for minors), this must be justified (such as no contact with the other parent for over a year).
Exclusion Criteria:
- Not corresponding to the targeted age range;
- Subject with contraindications to an MRI examination (pacemaker or neurosensory stimulator or implantable defibrillator, cochlear implants, ferromagnetic foreign bodies in the eyes or brain near neural structures, metal prostheses, patient agitation: non-cooperative or agitated patients, minors, claustrophobic subjects, pregnant women, ventriculoperitoneal neurosurgical shunt valves, dental braces);
- Subject with chronic alcohol or drug use;
- Abuse or dependence on substances (except nicotine) or toxic substances for more than 5 years or having led to comas (overdoses);
- Subject with sudden-onset cognitive disorders that could indicate a stroke; a history of head trauma with loss of consciousness for more than 1 hour, or encephalitis;
- Subject with chronic neurological, psychiatric, endocrine, hepatic, or infectious conditions;
- Subject with a history of major illness (diabetes, chronic lung disease, severe cardiac, metabolic, hematological, endocrine, or immunological disorder, cancer);
- Subject on medication: taking medications likely to interfere with brain imaging measurements (psychotropics, anxiolytic hypnotics, neuroleptics, anti-Parkinsonians, benzodiazepines, steroidal anti-inflammatories, antiepileptics, central analgesics, and muscle relaxants);
- Color blindness;
- Inability to comply with the study for geographical or psychiatric reasons;
- Tattoo incompatible with MRI;
- Cerebral palsy;
- Fine motor skills disorder;
- Pregnant women at the time of inclusion;
- Adult subjects under legal protection or unable to give consent (article L.1121-8 of the French Public Health Code) (under guardianship or curatorship);
- Children and parents under legal protection measures
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Myelin
Time Frame: Day 1
|
Myelin Levels : Regional variations of Fractional Anisotropy (FA)
|
Day 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Working Memory
Time Frame: Day 1
|
Spatial Span from CANTAB - Units on a Scale |
Day 1
|
|
Inhibitory skills
Time Frame: Day 1
|
Stop Signal Task from CANTAB and CHEXI, TEXI and ADEXI self-questionnaires - Units on a Scale |
Day 1
|
|
Planning skills
Time Frame: Day 1
|
One Touch Stockings of Cambridge - Units on a Scale
|
Day 1
|
|
Decision-making and risk-taking
Time Frame: Day 1
|
Cambridge Gambling Task from CANTAB - Units on a Scale
|
Day 1
|
|
Reading skills
Time Frame: Day 1
|
Text, word and pseudoword reading and metaphonology from EVALEO 6-15/ECLA16+/EXALANG - Units on a Scale
|
Day 1
|
|
IQ
Time Frame: Day 1
|
Raven's Standard Progressive Matrices (SPM) - Units on a Scale
|
Day 1
|
|
Reasoning
Time Frame: Day 1
|
Cognitive Reasoning Task - Units on a Scale
|
Day 1
|
|
Social Cognition
Time Frame: Day 1
|
Tom-15 task - Units on a Scale
|
Day 1
|
|
Visuospatial attention
Time Frame: Day 1
|
Multiple Object Tracking task from CRAB - Units on a Scale
|
Day 1
|
|
Wellbeing questionnaire
Time Frame: Day 1
|
KIDSCREEN 27 for minor participants and SF-36 for adults - Units on a Scale
|
Day 1
|
|
Behavior questionnaire
Time Frame: Day 1
|
BIS/BAS scales - Units on a Scale
|
Day 1
|
|
Self-regulation questionnaire
Time Frame: Day 1
|
DERS-F - Units on a Scale
|
Day 1
|
|
Demographics questionnaire
Time Frame: Day 1
|
Age, sex, level of studies, etc.
|
Day 1
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 12, 2024
Primary Completion (Estimated)
July 1, 2028
Study Completion (Estimated)
July 1, 2028
Study Registration Dates
First Submitted
July 11, 2024
First Submitted That Met QC Criteria
March 7, 2025
First Posted (Actual)
March 11, 2025
Study Record Updates
Last Update Posted (Estimated)
September 2, 2025
Last Update Submitted That Met QC Criteria
August 25, 2025
Last Verified
August 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- D23-P028
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.